CONTEXT: Chemerin is a novel adipokine previously associated with metabolic syndrome phenotypes in a small sample of subjects from Mauritius. OBJECTIVE: The aim of the study was to determine whether plasma chemerin levels were associated with metabolic syndrome phenotypes in a larger sample from a second, unrelated human population. DESIGN, SETTING, PATIENTS, AND INTERVENTION: Plasma samples were obtained from the San Antonio Family Heart Study (SAFHS), a large family-based genetic epidemiological study including 1431 Mexican-American individuals. Individuals were randomly sampled without regard to phenotype or disease status. This sample is well-characterized for a variety of phenotypes related to the metabolic syndrome. MAIN OUTCOMES: Plasma chemerin levels were measured by sandwich ELISA. Linear regression and correlation analyses were used to determine associations between plasma chemerin levels and metabolic syndrome phenotypes. RESULTS: Circulating chemerin levels were significantly higher in nondiabetic subjects with body mass index (BMI) greater than 30 kg/m(2) compared with those with a BMI below 25 kg/m(2) (P < 0.0001). Plasma chemerin levels were significantly associated with metabolic syndrome-related parameters, including BMI (P < 0.0001), fasting serum insulin (P < 0.0001), triglycerides (P < 0.0001), and high-density lipoprotein cholesterol (P = 0.00014), independent of age and sex in nondiabetic subjects. CONCLUSION: Circulating chemerin levels were associated with metabolic syndrome phenotypes in a second, unrelated human population. This replicated result using a large human sample suggests that chemerin may be involved in the development of the metabolic syndrome.
CONTEXT: Chemerin is a novel adipokine previously associated with metabolic syndrome phenotypes in a small sample of subjects from Mauritius. OBJECTIVE: The aim of the study was to determine whether plasma chemerin levels were associated with metabolic syndrome phenotypes in a larger sample from a second, unrelated human population. DESIGN, SETTING, PATIENTS, AND INTERVENTION: Plasma samples were obtained from the San Antonio Family Heart Study (SAFHS), a large family-based genetic epidemiological study including 1431 Mexican-American individuals. Individuals were randomly sampled without regard to phenotype or disease status. This sample is well-characterized for a variety of phenotypes related to the metabolic syndrome. MAIN OUTCOMES: Plasma chemerin levels were measured by sandwich ELISA. Linear regression and correlation analyses were used to determine associations between plasma chemerin levels and metabolic syndrome phenotypes. RESULTS: Circulating chemerin levels were significantly higher in nondiabetic subjects with body mass index (BMI) greater than 30 kg/m(2) compared with those with a BMI below 25 kg/m(2) (P < 0.0001). Plasma chemerin levels were significantly associated with metabolic syndrome-related parameters, including BMI (P < 0.0001), fasting serum insulin (P < 0.0001), triglycerides (P < 0.0001), and high-density lipoprotein cholesterol (P = 0.00014), independent of age and sex in nondiabetic subjects. CONCLUSION: Circulating chemerin levels were associated with metabolic syndrome phenotypes in a second, unrelated human population. This replicated result using a large human sample suggests that chemerin may be involved in the development of the metabolic syndrome.
Authors: M Straczkowski; I Kowalska; A Nikolajuk; E Otziomek; A Adamska; M Karolczuk-Zarachowicz; M Gorska Journal: Int J Obes (Lond) Date: 2006-06-13 Impact factor: 5.095
Authors: B D Mitchell; L A Almasy; D L Rainwater; J L Schneider; J Blangero; M P Stern; J W MacCluer Journal: Am J Epidemiol Date: 1999-06-01 Impact factor: 4.897
Authors: C-S Kim; H-S Park; T Kawada; J-H Kim; D Lim; N E Hubbard; B-S Kwon; K L Erickson; R Yu Journal: Int J Obes (Lond) Date: 2006-03-14 Impact factor: 5.095
Authors: Kerry B Goralski; Tanya C McCarthy; Elyisha A Hanniman; Brian A Zabel; Eugene C Butcher; Sebastian D Parlee; Shanmugam Muruganandan; Christopher J Sinal Journal: J Biol Chem Date: 2007-07-16 Impact factor: 5.157
Authors: Jesse W Lloyd; Kristin A Evans; Kristy M Zerfass; Michael E Holmstrup; Jill A Kanaley; Stefan Keslacy Journal: Diabetes Metab Syndr Date: 2015-05-05
Authors: Gökhan Aksan; Sinan İnci; Gökay Nar; Korhan Soylu; Ömer Gedikli; Serkan Yüksel; Metin Özdemir; Rukiye Nar; Murat Meriç; Mahmut Şahin Journal: Int J Clin Exp Med Date: 2014-12-08
Authors: Shanmugam Muruganandan; Sebastian D Parlee; Jillian L Rourke; Matthew C Ernst; Kerry B Goralski; Christopher J Sinal Journal: J Biol Chem Date: 2011-05-14 Impact factor: 5.157